PARP, topoisomerase, and other DDR inhibitors are currently under clinical investigation to determine their safety and efficacy in patients with GBM.11, 23, 50 These studies can be expanded to include DMC1 as an inhibitor of HR. Here, DMC1 is linked to glioblastoma.